Evaluates gas-phase unfolding's impact on agonism in engineered antibodies, suggesting new biotherapeutic developments.
Human (h)IgG2 monoclonal antibodies (mAbs) are potent agonists due, in part, to their ability to undergo disulfide shuffling within their hinge regions. Herein, we describe a rapid, sensitive, collision-induced unfolding (CIU) assay that possesses a predictive relationship between gas-phase protein unfolding and agonism in hIgG2 variants. Furthermore, our results highlight the significance of hinge engineering in tuning mAb structure-function relationships for the development of future biotherapeutics. The agonistic activity of IgG2 antibodies depends, in part, on the flexibility of their hinge region, which is slow to measure in full-length antibodies. Here, the authors develop a rapid mass spectrometry assay that gauges this flexibility and predicts the agonism of engineered antibody variants.
No takes yet. Share an insight, caveat, or question.
Villafuerte-Vega et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: